How to Buy Adherium Ltd Shares in Australia [2025]

Key Takeaways

• Adherium Ltd (ASX:ADR) is an Australian digital health company focusing on smart inhaler technology for asthma and COPD management.
• Investors can buy ADR shares in Australia through platforms like moomoo that support ASX and US markets.
• Despite strong revenue growth in FY23, FY24 saw a 73.8% revenue drop and wider net losses due to strategic shifts.
• As of Nov 2025, ADR trades at AUD 0.004 with low liquidity, no dividends, and high institutional investor support.
• Outlook depends on successful commercialization in the US and strategic partnerships amid financial challenges.

Adherium Ltd (ADR.AU) is an Australian-based digital health company that specialises in respiratory remote patient monitoring through its range of smart inhaler devices and connected software solutions. Focused largely on global markets with revenue mainly from Europe and North America, Adherium aims to improve medication adherence in patients with asthma and COPD by leveraging innovative medical technology.

How to buy Adherium Ltd (ADR) stock in Australia?

If you're living in Australia and want to buy Adherium Ltd (ASX:ADR) stock, you're not alone. As a digital health company focusing on respiratory disease solutions, Adherium draws significant interest from tech-savvy investors. Follow these steps for a smooth investing experience in the US and Australian markets.

Step 1: Pick the best share trading app for US markets

Your first step is choosing a trading platform that supports both Australian and international stock purchases. For simplicity and efficiency, moomoo is a strong choice. It provides seamless access to US and AU markets within one intuitive app — a big plus for busy Australian professionals who need to invest with minimal effort.

When evaluating moomoo, consider factors like brokerage fees, market access (ASX, NASDAQ, NYSE), user interface ease, real-time data availability, and research tools. For first-time and time-poor investors, moomoo’s mobile-first design and competitive pricing structure make it suitable for buying Adherium Ltd stock from Australia.

Step 2: Choose the correct account type and open a share trading account

To buy Adherium Ltd shares, the next step is opening a brokerage account. Choose the right account type based on your financial goals and setup:

Individual Account: Suitable for personal investing with full control and responsibility.
Company Account: Allows trading on behalf of a registered business entity.
Trust Account: Used within family or discretionary trusts, often for tax planning.
SMSF Account: For self-managed super fund investors seeking long-term exposure.

Australian investors will typically need to provide personal identification documents (like a driver’s licence or passport), tax file number (TFN), and bank details. To trade US stocks, you’ll also need to complete a W-8BEN form to declare your non-US resident tax status, which ensures correct dividend withholding rates.

Step 3: Fund your account

After your account setup, link your Australian bank account and transfer funds. Depending on the platform, funding can be near-instant or take a few days. For Adherium stock trading, make sure your account supports AUD to USD conversion if you're accessing international markets.

Step 4: Research Adherium Ltd's fundamentals

Before investing, assess Adherium’s financials and strategy. The company is active in digital respiratory health, generating most of its revenue from Europe and North America. Check metrics like revenue growth (503.97% YoY in FY23), gross profit margin (79.03%), and liquidity ratios (Current Ratio: 3.61). Though currently unprofitable, Adherium’s focus on innovative eHealth solutions and large partnerships may offer long-term upside.

Step 5: Set a budget for your Adherium Ltd stock purchase

Decide how much you want to allocate based on your overall portfolio and savings. Prioritise building an emergency fund before investing. If your budget is limited, check if the platform supports fractional shares, so you can still get exposure to Adherium Ltd without buying a full share.

Step 6: Decide when to buy Adherium Ltd stock

Time your buy decision by reviewing the stock’s recent performance and market trends. Adherium’s stock has traded around $0.004 to $0.005 over the past month, experiencing low liquidity and wider swings. If you prefer a long-term hold, consider dollar-cost averaging to reduce entry risk.

Step 7: Monitor your stock portfolio

Once you’ve made the investment, track Adherium's updates, financial reports, and stock performance. Use features in moomoo like watchlists, price alerts, and news integration to stay informed. Review your holding regularly alongside your financial goals and broader market conditions.

What is Adherium Ltd?

Adherium Ltd (ASX:ADR) is a digital health company specialising in the development and commercialisation of connected respiratory monitoring devices aimed at improving medication adherence and chronic disease management. Its flagship product suite, the Hailie® platform, integrates sensors, mobile and desktop applications, and data analytics to remotely monitor patients with asthma and COPD. Headquartered in Australia, Adherium collaborates with healthcare providers and pharmaceutical companies to enhance therapeutic outcomes through technology. The company’s largest shareholders include Regal Partners Limited, Trudell Medical Limited, and Bioscience Managers Pty Ltd, each holding significant stakes that reflect strong institutional support in the medtech innovation sector.

How has Adherium Ltd stock price performed?

Adherium Ltd (ASX:ADR) has been trading at the lower end of the ASX small-cap medical devices sector, with the ADR stock price exhibiting relatively flat momentum in recent weeks. As a penny stock, Adherium stock has shown minimal volatility and volume fluctuation, typical of thinly traded securities in the emerging biotech space. Investors tracking the Adherium stock price performance should note that it has maintained a steady range while staying under key moving average thresholds, indicating low short-term momentum despite occasional speculative interest.

Looking back at historical trading activity, the ADR stock price peaked at AUD 0.005 during October 2025, while remaining at AUD 0.004 for most recent trading sessions. While this suggests consolidation rather than breakout potential, long-term movements may be influenced by future capital raisings, clinical trial outcomes, or partnership developments in its digital respiratory health platform. For those researching how to buy Adherium stock in Australia, it is essential to evaluate not just price movement, but also fundamental measures reflective of the company’s financial condition.

Key financial metrics for Adherium Ltd

Source: moomoo, data as of 25-11-11

Adherium Ltd price forecast

Forecasting the Adherium stock price involves speculation, as the company currently does not provide earnings guidance or analyst estimates. However, with its historically high gross profit rate and enhanced capital backing from institutional investors like Regal Partners and Trudell Medical, ADR’s future price trajectory could benefit from scaling revenues or FDA-related developments. Prospective investors should stay informed on corporate disclosures and regulatory announcements that may influence Adherium Ltd price direction in the next financial year.

Adherium Ltd earnings FY2024 analysis

Source: Adherium Annual Report, data as of 2024-06-30.

Adherium Ltd’s FY2024 earnings results, released after the latest Adherium Ltd earnings date, reflected a significant shift in business strategy, impacting its topline performance. The company reported revenue of only $0.84 million, a staggering 73.8% drop quarter-over-quarter from $3.20 million in FY2023. This was primarily due to Adherium’s redirection from clinical trials to focusing on commercialising remote monitoring services in the U.S. market. Think of it as a restaurant closing its buffet line to refocus as a fine-dining spot — the customer flow changes, and so does cashflow.

From the bottom-line perspective, Adherium posted a net loss of $10.22 million in FY2024, widening by over 53% compared to the previous year. The administrative costs also rose to $5.49 million, reflecting hiring and consulting costs associated with deeper engagements in the U.S. commercial market. During the latest Adherium Ltd earnings call, management reiterated confidence in their strategic pivot and announced partnerships with AMC Health and Tenovi. However, investors will need to monitor liquidity carefully, as the company ended the fiscal year with only $43,255 in cash, down sharply from over $6 million a year earlier — much like running a marathon while low on fuel. Liquidity support such as their new R&D loan facility will be crucial for survival and growth in upcoming quarters.

Does Adherium Ltd pay dividends?

When evaluating Adherium Ltd (ADR.AU) from a dividend investment perspective, one must consider that the healthcare technology company is still in its growth and capital-raising phase. Known for its proprietary Hailie platform, Adherium has strategically prioritized innovation and expansion over shareholder distributions. Despite its placement within the ASX’s healthcare sector, where some peers offer reliable returns via dividends, Adherium does not currently distribute regular dividends to investors.

The absence of an Adherium dividend policy reflects the company’s focus on operational growth and financial stability, as seen in its negative net profits and increased financing activities. Investors seeking stable income through dividends may look to other, more mature players in the medical devices and digital health industry. However, growth-oriented investors might still find value in Adherium’s long-term technological potential and its increasing momentum in key regions such as Europe and North America.

When is Adherium stock split?

The most recent Adherium stock split was a reverse stock split executed on December 4, 2023, where shareholders received 1 share for every 15 previously held (15-to-1 consolidation). This Adherium Ltd stock split was implemented to streamline its capital structure and potentially improve the ADR share price on the ASX by reducing the number of shares on issue. Although there have been no announcements regarding future Adherium stock splits as of November 2025, investors should monitor official ASX disclosures and broker communications for any updates related to changes in ADR stock structure.

What ETFs hold ADR.AU?

Adherium Ltd (ADR.AU) is a small-cap stock in the healthcare technology space. Due to its market size and liquidity, it is generally included in a limited number of exchange-traded funds (ETFs), mainly those that focus on Australian small-cap or healthcare-related equities.

• SPDR S&P/ASX Emerging Companies ETF (ASX: EMMG): This ETF typically holds a range of smaller Australian companies, and may include ADR.AU as part of its exposure to emerging players in the healthcare sector.
• VanEck Australian Equal Weight ETF (ASX: MVW): With a more diversified approach across sectors and market caps, ADR.AU may occasionally be represented depending on index rebalancing and weighting.
• BetaShares S&P/ASX Small Ordinaries Fund (ASX: EX20): Focused on smaller companies outside the top 20 ASX-listed stocks, this ETF may include ADR.AU based on index eligibility.

Which stocks are similar to ADR.AU?

If you're researching Adherium Ltd (ADR.AU) and looking for comparable companies, it's helpful to consider other stocks in the healthcare technology or medical device sectors that are similarly positioned in terms of market capitalisation, product focus, or stage of development.

• Respiri Ltd (RSH.AU) – An Australian health tech company specialising in remote patient monitoring and digital asthma management, offering a comparable business model and target market.
• Volpara Health Technologies Ltd (VHT.AU) – Focused on breast imaging analytics, Volpara is also in the medtech space leveraging software and data for clinical outcomes.
• ImpediMed Ltd (IPD.AU) – Operates in the bioimpedance medical technology field and shares ADR's focus on non-invasive health monitoring tools.
• Mach7 Technologies Ltd (M7T.AU) – Provides medical imaging data solutions and is a peer in the digital health data infrastructure space.
• Elsight Ltd (ELS.AU) – While not strictly medtech, Elsight works with connectivity solutions for critical communication, relevant to health-tech device integration.

Is it a good time to buy Adherium Ltd stock

Adherium Ltd (ASX:ADR) is trading at A$0.004 as of November 13, 2025, showing little price movement with narrow trading ranges for over a month. This stability might sound like a calm ocean, but investors should look beneath the surface. The company’s 2023 financials reveal rising annual revenue to A$3.19 million—up a massive 504% year over year—yet net losses remain steep at A$9.86 million. Its PE ratios are in the negative (-2.0 TTM), and technicals like RSI trending around 38.7 indicate weak momentum. Adding to the caution, recent technical indicators such as MACD and BIAS show persistently neutral to bearish sentiment, and the company has issued over 494 million new securities, potentially diluting shareholder value.

Investing in Adherium now could be like planting seeds in dry soil—it may sprout later, but there’s uncertainty in timing. While institutional investors like Regal Partners and Trudell Medical have increased holdings, retail investors should weigh risks including low liquidity, absence of dividends, and no earnings forecast data. Crucially, due diligence is essential, and given the company's speculative nature, it may only suit high-risk tolerance portfolios. Always consider speaking with a licensed financial adviser before taking a position in this micro-cap healthcare tech stock.

What is the Adherium Ltd outlook for 2025?

Adherium Ltd finds itself at a pivotal juncture in 2025. Despite a 503.97% year-over-year spike in revenue to AUD 3.19 million in FY2023, the company still reported a net loss of AUD 9.86 million. It's a bit like sprinting uphill—there’s momentum, but the climb remains steep. The digital health company, known for its Hailie platform that supports remote monitoring and medication adherence, faces ongoing challenges in commercialising its tech across Europe and North America, where 99% of its revenue is concentrated. As regulatory landscapes evolve—especially for connected health devices—Adherium must navigate compliance waters carefully while keeping innovation afloat.

Looking ahead, profitability may hinge on achieving scale and securing consistent reimbursement agreements with healthcare payers. With a market cap of just AUD 1.33 million as of November 11, 2025, and negative earnings per share of –0.002, investor confidence remains fragile. Yet, institutional backers such as Regal Partners and UBS Asset Management continue to increase holdings, suggesting strategic faith in its long-term vision. As digital healthcare becomes less of a novelty and more of a necessity in chronic disease management, Adherium's mission aligns with macro trends—but execution remains the wildcard in 2025's deck.

Final thoughts on how to buy Adherium Ltd stock

Buying Adherium Ltd (ASX:ADR) stock in Australia involves more than just picking a trading platform—it's about understanding the company's growth potential and risk profile. As a medtech innovator in remote respiratory monitoring, Adherium draws interest from tech-focused investors despite its current lack of profitability. To get started, choose a reliable platform like moomoo that supports ASX and international stocks, open the appropriate trading account, fund it in AUD or USD, and complete any required tax documentation such as the W-8BEN form. Then, carefully assess Adherium’s business fundamentals and set a budget that suits your risk tolerance.

If you’re ready to buy Adherium Ltd stock, remember it’s a speculative micro-cap investment with low liquidity and no dividends. Monitor corporate updates, financial disclosures, and broader market sentiment to track its future prospects. Dollar-cost averaging may be a smart approach for long-term exposure without committing a large sum upfront. Whether you’re investing based on innovation potential or institutional support, always align your decisions with your financial goals—and seek advice from a licensed financial adviser if needed.